BridgeBio Pharma
BBIO
BBIO
179 hedge funds and large institutions have $1.1B invested in BridgeBio Pharma in 2022 Q4 according to their latest regulatory filings, with 24 funds opening new positions, 55 increasing their positions, 71 reducing their positions, and 25 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more funds holding in top 10
Funds holding in top 10: →
less first-time investments, than exits
New positions opened: | Existing positions closed:
less funds holding
Funds holding: →
1.23% less ownership
Funds ownership: 97.96% → 96.72% (-1.2%)
23% less repeat investments, than reductions
Existing positions increased: 55 | Existing positions reduced: 71
24% less capital invested
Capital invested by funds: $1.44B → $1.1B (-$342M)
Holders
179
Holding in Top 10
3
Calls
$2.08M
Puts
$761K
Top Buyers
| 1 | +$8.12M | |
| 2 | +$6.87M | |
| 3 | +$6.67M | |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$4.47M |
| 5 |
BlackRock
New York
|
+$3.83M |
Top Sellers
| 1 | -$10.4M | |
| 2 | -$8.23M | |
| 3 | -$6M | |
| 4 |
TCM
Tang Capital Management
San Diego,
California
|
-$5.82M |
| 5 |
Baillie Gifford & Co
Edinburgh,
United Kingdom
|
-$4.97M |